Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer

Cancer Drug Resistance(2022)10.20517/cdr.2022.31Source: DataRank Database

Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer is a research paper published in Cancer Drug Resistance (2022). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access16 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (13)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Richard Hoefer ORCID,Mary L. Guye ORCID,Harry D. Bear ORCID,Amy Tang ORCID

Live enrichment

PubMed:36176751 PMC:PMC9511813

DOD-BCRP Level II Breakthrough Award

Grant: BC180907

National Institutes of Health National Cancer Institute

Grant: R01 CA140550

the Center for Innovative Technology (CIT) - Commonwealth Research Commercialization Fund

Grant: MF14S-009-LS

National Institutes of Health

Grant: 5R01CA140550-05

SIAH2-Dependent Proteolysis in Cell Migration, Tumor Growth and Cancer Metastasis

Dorothy G. Hoefer Foundation

goldLicense: cc-by

publisherhttps://cdrjournal.com/article/download/4902

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9511813

Europe_PMChttps://europepmc.org/articles/PMC9511813

Europe_PMChttps://europepmc.org/articles/PMC9511813?pdf=render

https://doi.org/10.20517/cdr.2022.31

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

Chemo-resistanceTriple-negative Breast Cancer (Tnbc)Ubiquitin-mediated ProteolysisPatient Risk StratificationNeoadjuvant Chemotherapy PrognosisEgfr/K-Ras/Siah Pathway Activation In TnbcPrecision Quantification Of Therapy EfficacyAnd Treatment OptimizationDetection Of Chemo-ResistanceSeven In Absentia (Sina) And Human Homologs Of Sina (Siah) E3 LigaseReview

Sustainable Development Goals

SDG 3: 3. Good health